J. Henri Bayle

Bellicum Pharmaceuticals (United States) — United States

Medicine · Health Sciences

21h-index3.6kcitations36works29.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(18), Immune Cell Function and Interaction(7), Immunotherapy and Immune Responses(6), Signaling Pathways in Disease(5), Pancreatic function and diabetes(4)

Publications35 total

PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
Nature Communications·2024· 29 citedOpen Access
Preclinical Development of Inducible MyD88/CD40 (iMC)-Enhanced Chimeric Antigen Receptor Natural Killer (GoCAR-NK) Cells to Target BCMA+ Tumors
Blood·2020· 1 cited
Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins
Molecular Therapy·2020· 24 citedOpen Access
Abstract 2194: Inducible MyD88/CD40 (iMC) enhances CAR-T cell expansion and persistence by overcoming T cell exhaustion
Cancer Research·2020
Abstract 2193: Small molecule inducible MyD88/CD40 (iMC) in CAR-T cells can repolarize M2 macrophage to an anti-tumor M1 phenotype
Cancer Research·2020
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Blood Advances·2020· 66 citedOpen Access
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Leukemia·2019· 78 citedOpen Access
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
Molecular Therapy — Oncolytics·2018· 83 citedOpen Access
Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40
Blood·2018· 2 cited
Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion
Blood·2018
Abstract LB-141: A unified dual-switch CAR vector to target solid cancer with controllable "on" and "off" states
Cancer Research·2018
Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer
Blood·2017
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
Molecular Therapy·2017· 103 citedOpen Access
Abstract LB-184: Dual-switchGoCAR-T cells: small molecule-regulated “GO” and “STOP” switches to target solid cancer <i>in vivo</i>
Cancer Research·2017
Abstract 3745: Dual-switch TCR: A two-ligand system to control PRAME TCR-modified T cell proliferation and death using inducible MyD88/CD40 and caspase-9
Cancer Research·2017
Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication By CD123-Specific Chimeric Antigen Receptor T Cells
Blood·2016· 2 cited
Abstract A057: Uni-CIDeCAR-T cells: MyD88/CD40-enhanced, Ab-directed CAR incorporating the CaspaCIDe® safety switch
Cancer Immunology Research·2016· 3 cited
Ligands for FKBP12 Increase Ca2+ Influx and Protein Synthesis to Improve Skeletal Muscle Function
Journal of Biological Chemistry·2014· 26 citedOpen Access
Sudden Infant Death Syndrome in Mice With an Inherited Mutation in <i>RyR2</i>
Circulation Arrhythmia and Electrophysiology·2009· 26 citedOpen Access
Induced chromosome deletions cause hypersociability and other features of Williams–Beuren syndrome in mice
EMBO Molecular Medicine·2009· 106 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Aaron E. Foster(16), David M. Spencer(13), Matthew R. Collinson-Pautz(8), MyLinh Duong(8), Mary E. Brandt(7), Aruna Mahendravada(6), An Lu(6), Kevin M. Slawin(6), Kelly Sharp(6), Kryn Stankunas(5), Gerald R. Crabtree(5), Éva Morschl(5), Jason E. Gestwicki(4), Robert B. Rose(4), Robert H. Crabtree(4), Arnold J. Levine(3), Thomas J. Wandless(3), Nicholas Shinners(3), Wei-Chun Chang(3), Jeannette Crisostomo(3)